Semaglutide Research
Clinical Trial: Semaglutide Versus Placebo in NIT-Assessed MASH-A Multicenter Randomised Placebo-Controlled Trial (SAMARA)
Alimentary Pharmacology & Therapeutics·April 1, 2026
Veeral Ajmera, Raj Vuppalanchi, Mandana Khalili, Muhammad Y. Sheikh, Joseph Risser, Samuel Klein, et al., Rohit Loomba
Summary
Semaglutide significantly reduced FAST score (-0.28 vs -0.12, p=0.002). More recipients achieved ≥5% weight loss (64% vs 8.3%) and ≥30% MRI-PDFF reduction (60% vs 17%).
Study Details
Study Design
Multicentre, randomized, double-blind, placebo-controlled 52-week trial
Indication
At-risk MASH (metabolic dysfunction-associated steatohepatitis)
Intervention
Semaglutide 2.4 mg subcutaneous weekly vs placebo
Species
Human
Sample Size
55 subjects